Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infection

NCT05683548 is registered in ClinicalTrials.gov with Replicor Inc. as lead sponsor.

NCT NCT05683548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05683548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Compassionate Use Access to REP 2139-Mg for the Treatment of Chronic HBV Infection or Chronic HBV / HDV Co-infection
Lead sponsor
Replicor Inc.
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

ascites hepatic, cirrhosis, liver, decompensated cirrhosis, hepatocellular carcinoma, varices, esophageal, viral hepatitis b, viral hepatitis d